OWC Pharmaceutical Research Advisory Board Member to Participate in the First Bloomberg Intelligence Sponsored Cannabis Event
PETACH TIKVA, Israel, November 18, 2016 /PRNewswire/ --
PETACH TIKVA, Israel, November 18, 2016: OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company"), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced that Jeffrey Friedland, a member of the Company's Advisory Board, will be participating in Bloomberg Intelligence's first cannabis-related event; Cannabis Trends & Legalization Implications.
(Logo: http://photos.prnewswire.com/prnh/20150311/734965-a )
(Logo: http://photos.prnewswire.com/prnh/20150311/734965-b )
Cannabis Trends & Legalization Implications will be held Monday, November 21st in New York City, and will explore the most important legal, medical and financial developments and issues associated with America's marijuana industry. The session will start with a panel of key players in the space, dissecting the implications and opportunities associated with cannabis decriminalization across the United States. It will be moderated by Kenneth Shea, Senior Consumer Products Analyst of Bloomberg Intelligence.
It is anticipated that Mr. Friedland, who is also the author of Marijuana: The World's Most Misunderstood Plant, will have the opportunity to highlight to event attendees the progress that OWC has made with its medical cannabis research in Israel, and the positive impact that OWC and other Israeli companies are having on state-licensed U.S. growers and extractors.
When asked about his participation in the Bloomberg event, Mr. Friedland stated, "I've been involved in the legal cannabis industry for several years now; including as the CEO of INTIVA Inc., an investor and operator of businesses in the global cannabis market. I view the cannabis industry as an emerging global market with several sectors, including medical, recreational, services and equipment, each with their own unique opportunities for investors and entrepreneurs. While many industry participants are very speculative, as the legalization of both recreational and medical cannabis spreads, I've concluded that the real money will be made by companies that not only harness science to differentiate their products, but are also able to get those products into the marketplace."
Friedland went on to say, "There are many cannabis companies that are publicly-traded, from GW Pharmaceuticals (GWPH) to smaller public companies such as OWC, which Intiva invested in during the summer of 2014 when OWC's research into the effects of cannabis on conditions including multiple myeloma, psoriasis and PTSD caught our attention; I joined the Company's advisory board earlier this year. OWC's recent announcements of partnerships to bring its cannabis-based topical psoriasis product to licensed markets in the US and EU are significant events for the Company, and indicate positive directions for the execution of their business model."
Subject to his schedule, Mr. Friedland may be available to meet privately with OWC shareholders to discuss his view of OWC's future.
About Bloomberg Intelligence
Bloomberg Intelligence is the research arm of Bloomberg L.P. It provides in-depth analysis and data sets on industries, companies and credit, government economic and litigation factors that impact decision making.
About Jeffrey Friedland
Jeffrey Friedland is an emerging market pioneer -- his firm, Friedland Global Capital, was one of the first American investment banks to establish a presence in China -- and he can now be found on the forefront of the cannabis movement. In his book, Marijuana: The World's Most Misunderstood Plant guides the reader through the plant's rich, and sometimes scandalous history, explains how and why cannabis affects us, describes the methods of breeding, cultivating and processing that plant, and perhaps most importantly, provides an overview of the most recent research into its potential of cannabinoid-based medicine.
Mr. Friedland was an owner of two retail cannabis stores in Colorado in the mountain resort towns of Breckenridge and Crested Butte, and a cannabis cultivation facility located south of Steamboat Springs. These businesses were featured in CNN's 2015 reality series, High Profits. He is also CEO of INTIVA Inc., a multi-faceted life sciences company in the worldwide legal cannabis industry that has established businesses and made investments in the cannabis industry in California, Colorado, Canada and Israel.
Mr. Friedland is also CEO of the financial services firm Friedland Global Capital, which provides corporate finance and strategic advisory services to entrepreneurial companies in emerging markets. He has been the CEO of a Nasdaq-listed company, a member of the board of directors and chairman of the audit committee of a New York Stock Exchange-listed company, and the chairman of the supervisory board of a company listed on the Regulated Market of the Frankfurt Stock Exchange. Mr. Friedland has been featured, interviewed or quoted in numerous publications including the Wall Street Journal, USA Today, The South China Morning Post (Hong Kong), NBC.com, Forbes, CNBC and its predecessor, Financial News Network, Bloomberg Information Radio, and Bloomberg TV. This is the second book he has written. His first book, All Roads Lead to China: An Investor Road Map to the World's Fastest Growing Economy, was published in 2014.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact Information: In Israel: Ziv Turner, Chief Executive Officer - One World Cannabis Ltd. Email: email@example.com Tel: +972-(0)3-7582659
SOURCE OWC Pharmaceutical Research Corp.